Turning to 2025 guidance, Lilly noted that new medicines and new uses of existing medicines, expansion of production, and ...

Reverse engineering these drugs is a tough challenge without being sued by the three main companies operating in this market (Novo Nordisk, Eli Lilly and Sanofi). Moreover, the latter, in order to ...

Just how much Medicare price negotiations will negatively impact Novo Nordisk, though, depends on what the final negotiated ...

Weight loss goals may be at the forefront of many New Year's resolutions, which could push the exuberance for Eli Lilly LLY ...

The story of Eli Lilly and Novo Nordisk’s GLP-1 dominance is likely ... Pfizer and finally Sanofi in the projected rankings. In terms of drug sales buoying those company rankings, Lilly ...

Eli Lilly (NYSE: LLY) and Novo Nordisk (NYSE: NVO) benefit from innovative treatments for obesity and diabetes. Start Your Mornings Smarter! Wake up with Breakfast news in your inbox every market day.

The move intensifies an ongoing legal battle, as Novo Nordisk joins its major competitor Eli Lilly in opposing a recent initiative by the Outsourcing Facilities Association to include liraglutide in ...

The 'big three' insulin producers Novo Nordisk, Eli Lilly, and Sanofi are being sued by the state of California for allegedly working together to set artificially inflated prices for their products.

County Public Schools has joined dozens of other school systems and institutions in suing pharmaceutical and pharmacy companies, alleging that the companies manipulated the prices of insulin and other ...

Blockbuster weight loss medications from Novo Nordisk (NVO) and Eli Lilly (NYSE:LLY) lead Evaluate Pharma’s list of best-selling drugs projected for 2025 after the incretins pushed Bristol Myers ...

Novo Nordisk offered a cash card program and some price cuts in 2020, and Sanofi offered the Medicare $35 cap to senior citizens in 2021. However, Eli Lilly is the first to offer such a sweeping ...

Novo Nordisk has made its smart insulin pens ... The Danish pharma is trying to stay ahead of arch rivals Eli Lilly and Sanofi in an increasingly competitive insulin market, as well as tapping ...